Physician profile
Luga Podesta
NPI 1184680084
$205,779.74
in general payments reported to CMS, 2019-2025
9 companies · $69K in 2025
The $69K reported for 2025 was more than what 99% of Sports Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $27K · 2021: $18K · 2022: $4,170 · 2023: $19K · 2024: $15K · 2025: $69K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $86K · Consulting Fee: $12K · Travel and Lodging: $2,709 · Food and Beverage: $2,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $86,145.00 |
| Consulting Fee | $12,412.50 |
| Travel and Lodging | $2,708.80 |
| Food and Beverage | $2,460.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $204,329.45 | 2019-2025 | Arthrex |
| Ge Healthcare | $507.15 | 2022-2024 | |
| Smith+Nephew, INC. | $308.93 | 2023-2024 | Cap-Fix, Acufex |
| Bioventus LLC | $268.08 | 2019-2025 | Xcell |
| Boston Scientific Corporation | $168.24 | 2022 | |
| Stryker Corporation | $142.45 | 2019 | |
| Crossroads Orthopedics, LLC | $26.67 | 2019 | |
| Ferring Pharmaceuticals INC. | $17.12 | 2022 | |
| Genentech USA, INC. | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luga Podesta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.